Zenrelia (ilunocitinib) tablets for Dogs, 4.8mg

Zenrelia relieves itching in dogs due to allergic dermatitis and controls atopic dermatitis Zenrelia works fast, providing visible improvements in itch* * Forster S, Boegel A, Despa S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology. 2025; 1–10 Ilunocitinib, the active ingredient in Zenrelia, works by reducing the itch and inflammatory response in your dog's skin due to allergies The most common side effects reported with this dog dermatitis treatment were vomiting, diarrhea and tiredness; see package insert including the Boxed Warning The once-daily tablet can be given with or without food from the comfort of your home SAFETY WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.